Antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions and are becoming the molecules of choice for further combination therapies and cell engineering. Current developments and clinical successes are summarised by experts in the drug development field. A must read for immunologists, clinical scientists and novel drug developers.
Antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions and are becoming the molecules of choice for further combination therapies and cell engineering. Current developments and clinical successes are summarised by experts in the drug development field. A must read for immunologists, clinical scientists and novel drug developers.
Artikelnr. des Verlages: 11930006, 978-3-540-73258-7
2008
Seitenzahl: 396
Erscheinungstermin: 22. November 2007
Englisch
Abmessung: 241mm x 160mm x 27mm
Gewicht: 760g
ISBN-13: 9783540732587
ISBN-10: 3540732586
Artikelnr.: 23030288
Herstellerkennzeichnung
Books on Demand GmbH
In de Tarpen 42
22848 Norderstedt
info@bod.de
040 53433511
Inhaltsangabe
Historical Development of Monoclonal Antibody Therapeutics.- Preclinical Safety Evaluation of Monoclonal Antibodies.- Molecular Developments in Antibody Production.- Engineering Antibodies for Stability and Efficient Folding.- Human Monoclonal Antibodies from Transgenic Mice.- Antibodies to Cytokines.- Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future.- Therapeutic Anti-VEGF Antibodies.- Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab.- Antibodies to Cell Markers.- Anti-CD20Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus.- Herceptin.- The Use of CD3-Specific Antibodies in Autoimmune Diabetes: A Step Toward the Induction of Immune Tolerance in the Clinic.- Monoclonal Antibody Therapy for Prostate Cancer.- Anti-IgE and Other Antibody Targets in Asthma.- Development of Antibody-Based Cellular and Molecular Therapies.- Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors.- The T-Body Approach: Redirecting T Cells with Antibody Specificity.- Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential.
Historical Development of Monoclonal Antibody Therapeutics.- Preclinical Safety Evaluation of Monoclonal Antibodies.- Molecular Developments in Antibody Production.- Engineering Antibodies for Stability and Efficient Folding.- Human Monoclonal Antibodies from Transgenic Mice.- Antibodies to Cytokines.- Anti-TNF Antibodies: Lessons from the Past, Roadmap for the Future.- Therapeutic Anti-VEGF Antibodies.- Humanized Antihuman IL-6 Receptor Antibody, Tocilizumab.- Antibodies to Cell Markers.- Anti-CD20Monoclonal Antibody in Rheumatoid Arthritis and Systemic Lupus Erythematosus.- Herceptin.- The Use of CD3-Specific Antibodies in Autoimmune Diabetes: A Step Toward the Induction of Immune Tolerance in the Clinic.- Monoclonal Antibody Therapy for Prostate Cancer.- Anti-IgE and Other Antibody Targets in Asthma.- Development of Antibody-Based Cellular and Molecular Therapies.- Cytokine, Chemokine, and Co-Stimulatory Fusion Proteins for the Immunotherapy of Solid Tumors.- The T-Body Approach: Redirecting T Cells with Antibody Specificity.- Intracellular Antibodies (Intrabodies) and Their Therapeutic Potential.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826